Oral available agents in the treatment of relapsing remitting multiple sclerosis: an overview of merits and culprits

@inproceedings{Thne2013OralAA,
  title={Oral available agents in the treatment of relapsing remitting multiple sclerosis: an overview of merits and culprits},
  author={Jan Th{\"o}ne and Gisa Ellrichmann},
  booktitle={Drug, healthcare and patient safety},
  year={2013}
}
Multiple sclerosis (MS) is a chronic immunological disease of the central nervous system characterized by early inflammatory demyelination and subsequent neurodegeneration. Major therapeutic progress has occurred during the past decade, in particular since the introduction of immunomodulatory agents, however, MS is still an incurable disease. In addition, parenteral application of the currently licensed drugs is associated with injection-related adverse events (AEs) and low patient compliance… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

PET imaging of disease progression and treatment effects in the experimental autoimmune encephalomyelitis rat model.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine • 2014
View 8 Excerpts
Highly Influenced

Multiple sclerosis: a review of the disease and treatment options.

The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists • 2014

References

Publications referenced by this paper.
Showing 1-10 of 43 references

Results of phase III BRAVO trial Reinforce Unique Profile of Laquinimod for MS [webpage on the Internet

CMSC INForMS
Hackensack: Consortium of the Multiple Sclerosis Centers; 2011. Available from: http://bit.Ly/oAuZD6. Accessed February 12, • 2012
View 9 Excerpts
Highly Influenced

Oral teriflunomide plus glatiramer acetate in relapsing multiple sclerosis [abstract P17

MS Freedman, JS Wolinsky, B Wamil
Int J MS Care • 2011
View 19 Excerpts
Highly Influenced

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

The New England journal of medicine • 2010
View 5 Excerpts
Highly Influenced

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.

The New England journal of medicine • 2012
View 14 Excerpts
Highly Influenced

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.

The New England journal of medicine • 2012
View 14 Excerpts
Highly Influenced

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.

The New England journal of medicine • 2010
View 3 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…